CD20 (Rituximab Biosimilar) Human mAb is a biosimilar antibody for Rituximab. Rituximab is a therapeutic human monoclonal antibody directed against CD20 which is expressed on various B cell cancers such as some forms of B cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, and B cell acute le...
Link B K, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent ly...
Monoclonal human IgM antibody against human CD20 Anti-hCD20-hIgM features the constant region of the human IgM isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymp...
[1] Shi, Yuankai, et al. "Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera®) in combination with CHOP in patients with previously untreated CD20﹐sitive diffuse large B〆ll lymphoma: A randomized, single lind, phase III clinical trial." Hematological O...
Human CD20 (Rituximab) antibody - Human IgG4 (S228P) Add to favorite 100 µg 3 x 100 µg hcd20-mab14 ￥1,485 Please contactour distributor You may also need :Anti-β-Gal-hIgG4 (S228P)|View more associated products▼ Human IgG4 (S228P) engineered monoclonal antibody (mAb) agains...
ELISA Data: Immobilized Human CD20 at 0.5ug/ml (100ul/Well), dose response curve for rituximab with the EC50 of 4.14nM determined by ELISA SPR Data: CD20,His Tag captured on anti-his chip can bind CD20 antibody Rituximab , with an affinity constant of 4.4 nM as determined in a SPR ass...
以CD20为靶点的单抗药物是一类治疗B细胞淋巴瘤的靶向药物，原研药为1997年罗氏制药有限公司上市的利妥昔单抗(rituximab)。目前上市的主要有三代抗CD20单克隆抗体药物：第1代抗CD20单抗：利妥昔单抗、替伊莫单抗（Ibritumomab Tiuxetan）、托西莫单抗（Tositumomab）第2代抗CD20单抗：奥法木单抗(ofatumumab)，维妥珠单抗（...
目前,靶向CD20单克隆抗体(简称“抗CD20单抗”)广泛应用于神经免疫相关疾病,越来越多的证据支持其在不同疾病临床应用中的安全性、耐受性和疗效。抗CD20单抗,如静脉注射人鼠嵌合型利妥昔单抗(rituximab)已在中国临床应用多年,皮下给药的新一代全人源抗CD20单抗奥法妥木单抗(ofatumumab)也在中国获批,其安全性和耐受性...
Ibritumomab tiuxetan is the combination of a mouse monoclonal antibody, ibritumomab, with tiuxetan which is a chelating agent for radioactive isotopes of yttrium or indium. Chemical Structures and Properties Rituximab is a chimeric monoclonal antibody ma ......
Chimeric antibody:Rituximab 1986 年,FDA 批准了Ortho Biotech开发的第一个鼠源抗体,Muromonab-CD3(OKT3),2008该公司和强生的子公司Centocor合并,并在2011年将合并公司改名为Janssen Biotech。在2010退市之前,OKT-3商业化由Janssen-Cilag负责推动,Janssen和Cilag,分别在1961年和1959年被强生收购,并将后者归入Janssen旗下...